ArticleScientific reports2026
Urinary complement C3 fragment levels and their clinical relevance in MPO-ANCA-associated vasculitis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Complement Dysregulation in Kidney Diseases: Mechanisms, Biomarkers, and Emerging Targeted Therapies.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) is an autoimmune disease characterized by systemic small-vessel inflammation. Complement activation, particularly through the alternative pathway, has been implicated in AAV pathogenesis. However, the role and clinical significance of urinary complement C3 fragments as non-invasive biomarkers for disease activity remain unclear. This cross-sectional study enrolled 22 AAV patients and 20 healthy controls. Urinary levels of C3a, C3b, iC3b, C3c, and C3d were measured using enzyme-linked immunosorbent assay (ELISA) and normalized to urinary creatinine. Between-group comparisons were performed using independent t-tests or Mann–Whitney U tests. Correlations and independent predictors of urinary complement fragments were evaluated using Spearman correlation and multivariate linear regression, respectively. All urinary complement C3 fragment levels were significantly elevated in AAV patients compared to healthy controls (all p < 0.01). Among AAV patients, urinary C3 fragments correlated strongly with Birmingham Vasculitis Activity Score (BVAS, r = 0.793–0.900), proteinuria (r = 0.551–0.735), and hematuria (r = 0.643–0.752) (all p < 0.01), but not with serum creatinine (p > 0.05). BVAS was an independent predictor of all C3 fragments (β = 0.458–0.760, all p < 0.05), while proteinuria independently predicted all except iC3b (β = 0.302–0.455, all p < 0.05). Urinary complement C3 fragments are elevated in AAV patients and closely associated with disease activity, independent of renal function. These findings support their potential utility as non-invasive biomarkers for monitoring AAV disease activity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.